Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Assets (2020 - 2026)

InMed Pharmaceuticals has reported Assets over the past 5 years, most recently at $11.2 million for Q4 2025.

  • For Q4 2025, Assets rose 31.63% year-over-year to $11.2 million; the TTM value through Dec 2025 reached $11.2 million, up 31.63%, while the annual FY2025 figure was $15.6 million, 31.78% up from the prior year.
  • Assets for Q4 2025 was $11.2 million at InMed Pharmaceuticals, down from $13.4 million in the prior quarter.
  • Over five years, Assets peaked at $19.4 million in Q4 2021 and troughed at $8.5 million in Q4 2024.
  • A 5-year average of $13.4 million and a median of $13.4 million in 2025 define the central range for Assets.
  • Biggest five-year swings in Assets: crashed 44.27% in 2024 and later soared 31.78% in 2025.
  • Year by year, Assets stood at $19.4 million in 2021, then dropped by 12.71% to $16.9 million in 2022, then fell by 9.84% to $15.3 million in 2023, then crashed by 44.27% to $8.5 million in 2024, then skyrocketed by 31.63% to $11.2 million in 2025.
  • Business Quant data shows Assets for INM at $11.2 million in Q4 2025, $13.4 million in Q3 2025, and $15.6 million in Q2 2025.